文献速递头痛与眩晕

Galcanezumab在既往2至4类偏头痛预防药物失败患者中的安全性与有效性(CONQUER):多中心随机双盲安慰剂对照3b期试验

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
PubMed 文献 · Lancet Neurol · 2020-09-16

CONQUER试验在12国64中心纳入462例既往2至4类预防药物失败(疗效或耐受性)的发作性或慢性偏头痛患者,1:1随机接受皮下安慰剂或galcanezumab 120 mg每月(首剂240 mg负荷)治疗3个月。治疗中出现的不良事件类型和数量两组相似。

要点

  • 对于既往2至4类预防药物失败的患者,galcanezumab安全且耐受性良好。
  • 治疗中出现不良事件发生率:安慰剂组53%(122/230),galcanezumab组51%(119/232)。

核心结论

  • Galcanezumab在既往多种标准预防治疗失败的偏头痛患者中优于安慰剂,安全且耐受性良好。

研究设计与样本

  • CONQUER为多中心、随机、双盲、安慰剂对照3b期试验,在12国64个中心进行。
  • 纳入18-75岁、偏头痛起病早于50岁、过去10年内因疗效或耐受性(或两者)记录有2至4类预防药物失败的发作者或慢性偏头痛患者。
  • 462例患者1:1随机接受皮下安慰剂或galcanezumab 120 mg每月(首剂240 mg负荷,分两次120 mg注射)治疗3个月。

主要发现

  • 治疗中出现不良事件:安慰剂组122/230(53%),galcanezumab组119/232(51%)。
  • 严重不良事件共4例,安慰剂组2例(1%),galcanezumab组2例(1%)。

临床怎么用

  • 对于既往2至4类标准预防药物失败或不耐受的偏头痛患者,galcanezumab可作为重要治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients who require migraine preventive treatment have not been able to tolerate or have not responded to multiple previous preventive medications. We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide, in patients with migraine who had not benefited from preventive medications from two to four categories. METHODS: CONQUER was a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial done at 64 sites (hospitals, clinics, or research centres) in 12 countries (Belgium, Canada, Czech Republic, France, Germany, Hungary, Japan, the Netherlands, South Korea, Spain, the UK, and the USA). Patients were 18-75 years of age, with episodic or chronic migraine, with migraine onset before the age of 50 years, who had a documented failure of preventive medications from two to four drug categories in the past 10 years owing to lack of efficacy or tolerability, or both. Patients were randomised 1:1 to receive subcutaneous placebo or galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for 3 months. For masking purposes, patients receiving placebo also received two injections during the first dosing visit. Randomisation was done by a computer-generated random sequence by means of an interactive web-response system stratified by country and migraine frequency (low frequency episodic migraine, four to fewer than eight migraine headache days per month; high frequency episodic migraine, eight to 14 migraine headache days per month and fewer than 15 headache days per month; chronic migraine, at least eight migraine headache days per month and at least 15 headache days per month). The primary endpoint was the overall mean change from baseline in number of monthly migraine headache days during the 3-month treatment period in all patients who were randomly assigned and received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03559257, and is now completed. FINDINGS: Between Sept 10, 2018, and March 21, 2019, 462 participants with episodic (269 [58%]) or chronic (193 [42%]) migraine were randomly assigned and received at least one injection with placebo (n=230) or galcanezumab (n=232). Galcanezumab-treated patients had significantly greater reduction in migraine headache days versus placebo across months 1-3. The galcanezumab group had on average 4·1 fewer monthly migraine headache days compared with baseline (13·4), while the placebo group had on average 1·0 fewer than at baseline (13·0; between-group difference -3·1 [95% CI -3·9 to -2·3]; p<0·0001; effect size=0·72). Types and number of treatment-emergent adverse events were similar between galcanezumab and placebo. Treatment-emergent adverse events were reported in 122 (53%) of 230 patients in the placebo group and 119 (51%) of 232 patients in the galcanezumab group. There were four serious adverse events during the study, two (1%) reported in the placebo group and two (1%) reported in the galcanezumab group. INTERPRETATION: Galcanezumab was superior to placebo in the preventive treatment of migraine and was safe and well tolerated in patients for whom multiple previous standard-of-care preventive treatments had failed. Galcanezumab might represent an important treatment option for patients who have not benefited from or tolerated previous standard-of-care treatments. FUNDING: Eli Lilly.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020. PMID: 32949542. doi:10.1016/S1474-4422(20)30279-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。